Novel biomarkers for early diagnosis of Acute Kidney Injury
Acute Kidney Injury (AKI) is a rapid loss of kidney function that can be triggered by a number of disease or disorder processes. AKI can result in life-threatening metabolic derangements, e.g. acidosis, high potassium levels, changes in body fluid balance, and effects to other organ systems. AKI is observed in 5% of hospitalized patients and associated with a high mortality. Knowing the specific patient status in disease progression over time is critical for choosing ideal treatment regimens, in particular in the acute disease phase. Biomarkers in use so far, such as serum creatinine and blood urea nitrogen, do not sufficiently allow for such precise resolution, raising a demand for new early stage markers.
The technology relates to the use of newly identified AKI biomarkers specific for early stages, allowing for detailed estimation of disease progression over time. The technology is based on the detection of three novel markers (confidential) alone or in combination with known markers. The novel AKI-markers are expressed with peak expression at 6 hours or 48 hours after AKI onset, respectively. The expression profiles allow the detection of the markers at mRNA and/or protein level in blood, tissue or urine samples, thus representing a valid diagnostic tool to facilitate AKI diagnosis and to monitor disease progression and resolution. So far, the assay format is based on mRNA microarray analysis, but can be extended to protein techniques.
Progression stage-specific biomarker expression was shown in a mouse AKI model using ischemia reperfusion injury and mRNA detection.
In-licensing for the development of diagnostic tools; collaboration opportunity.
A European and a US Patent Application are pending (unpublished, confidential).